All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

PHARMACOMPASS

Grow Your Pharma Business Digitally

Find Clinical Drug Pipeline Developments & Deals for Rhenium-186

All Data

Filters

×

FILTER DATA :

Therapeutic Area

Study Phase

Country

News Type

Company

Companies By Therapeutic Area

Development Status

NanoTx Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

The Boulder Peptide Society

Participation Not Confirmed

Update your events

Plus Therapeutics Announces Closing of Agreement to License Novel Oncology Platform with NanoTx Therapeutics

Lead Product(s): Rhenium-186

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Plus Therapeutics

Deal Size: $137.2 million Upfront Cash: $0.4 million

Deal Type: Licensing Agreement May 11, 2020

Details:

Plus Therapeutics closed its previously announced definitive agreement to license multiple rare cancer product candidates that includes, Rhenium-186-chelated NanoLiposome from NanoTx Therapeutics.